Related references
Note: Only part of the references are listed.Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
Fotios Loupakis et al.
BRITISH JOURNAL OF CANCER (2016)
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C. Cremolini et al.
ANNALS OF ONCOLOGY (2015)
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
Gang Zheng et al.
BMC CANCER (2015)
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
A. Rowland et al.
BRITISH JOURNAL OF CANCER (2015)
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
Frank A. Sinicrope et al.
CLINICAL CANCER RESEARCH (2015)
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Filippo Pietrantonio et al.
EUROPEAN JOURNAL OF CANCER (2015)
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial
George Pentheroudakis et al.
PLOS ONE (2015)
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
Christina Therkildsen et al.
ACTA ONCOLOGICA (2014)
Combined Microsatellite Instability and BRAF Gene Status As Biomarkers for Adjuvant Chemotherapy in Stage III Colorectal Cancer
Akira Ooki et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies
Dandan Cui et al.
MOLECULAR BIOLOGY REPORTS (2014)
BRAFV600E Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis
Dong Chen et al.
PLOS ONE (2014)
Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis
Zu-Yao Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A meta-analysis
Qi Xu et al.
JOURNAL OF DIGESTIVE DISEASES (2013)
Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial
Shuji Ogino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Clinicopathological relevance of BRAF mutations in human cancer
Sahar Pakneshan et al.
PATHOLOGY (2013)
Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
Shuji Ogino et al.
CLINICAL CANCER RESEARCH (2012)
Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
Patrick G. Gavin et al.
CLINICAL CANCER RESEARCH (2012)
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial
Steven R. Alberts et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
Arnaud D. Roth et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
Gholamreza Safaee Ardekani et al.
PLOS ONE (2012)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
Amy J. French et al.
CLINICAL CANCER RESEARCH (2008)
Share Paper
